Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Webster

Showing results (61-70 of 73) with videos related to

Pageof 8
Sort By:
Haematologica|March 20, 2025
Recognition, prevention, and management of adverse events associated with asparaginase / pegaspargase treatment of acute lymphoblastic leukemia in adults: consensus of an expert panelEmily Curran, Marlise R Luskin, Houda Alachkar, et al.
Scientific Reports|March 7, 2019
Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivoNicole D Vincelette, Husheng Ding, Amelia M Huehls, et al.
Haematologica|February 10, 2022
Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and <i>BCR-ABL</i>-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicinSabine Kayser, Chiara Sartor, Marlise R Luskin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2014
Pattern of frequent but nontargeted pharmacologic thromboprophylaxis for hospitalized patients with cancer at academic medical centers: a prospective, cross-sectional, multicenter studyJeffrey I Zwicker, Adam Rojan, Federico Campigotto, et al.
The Journal of Biological Chemistry|September 8, 2012
Chaperone activity of small heat shock proteins underlies therapeutic efficacy in experimental autoimmune encephalomyelitisMichael P Kurnellas, Sara E Brownell, Leon Su, et al.
Leukemia & Lymphoma|April 5, 2022
Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapyTheodoros Karantanos, Hua-Ling Tsai, Lukasz P Gondek, et al.
Haematologica|June 11, 2026
Evolution to complex karyotype disease in mono-allelic <i>TP53</i>-mutated myelodysplastic syndrome/acute myeloid leukemia: a cohort studyPriyanka Fernandes, Sergiu Pasca, Tania Jain, et al.
Cancer Medicine|November 14, 2023
A phase 2 and pharmacological study of sapanisertib in patients with relapsed and/or refractory acute lymphoblastic leukemiaAref Al-Kali, Ibrahim Aldoss, Pamela J Atherton, et al.
Haematologica|December 7, 2023
Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive diseaseSabine Kayser, Chiara Sartor, Fabio Giglio, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 9, 2021
Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center ExperienceAlexander Ambinder, Matthew Smith, Hua-Ling Tsai, et al.
Pageof 8

Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
Haematologica|March 20, 2025
Recognition, prevention, and management of adverse events associated with asparaginase / pegaspargase treatment of acute lymphoblastic leukemia in adults: consensus of an expert panelEmily Curran, Marlise R Luskin, Houda Alachkar, et al.
Scientific Reports|March 7, 2019
Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivoNicole D Vincelette, Husheng Ding, Amelia M Huehls, et al.
Haematologica|February 10, 2022
Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and <i>BCR-ABL</i>-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicinSabine Kayser, Chiara Sartor, Marlise R Luskin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2014
Pattern of frequent but nontargeted pharmacologic thromboprophylaxis for hospitalized patients with cancer at academic medical centers: a prospective, cross-sectional, multicenter studyJeffrey I Zwicker, Adam Rojan, Federico Campigotto, et al.
The Journal of Biological Chemistry|September 8, 2012
Chaperone activity of small heat shock proteins underlies therapeutic efficacy in experimental autoimmune encephalomyelitisMichael P Kurnellas, Sara E Brownell, Leon Su, et al.
Leukemia & Lymphoma|April 5, 2022
Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapyTheodoros Karantanos, Hua-Ling Tsai, Lukasz P Gondek, et al.
Haematologica|June 11, 2026
Evolution to complex karyotype disease in mono-allelic <i>TP53</i>-mutated myelodysplastic syndrome/acute myeloid leukemia: a cohort studyPriyanka Fernandes, Sergiu Pasca, Tania Jain, et al.
Cancer Medicine|November 14, 2023
A phase 2 and pharmacological study of sapanisertib in patients with relapsed and/or refractory acute lymphoblastic leukemiaAref Al-Kali, Ibrahim Aldoss, Pamela J Atherton, et al.
Haematologica|December 7, 2023
Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive diseaseSabine Kayser, Chiara Sartor, Fabio Giglio, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 9, 2021
Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center ExperienceAlexander Ambinder, Matthew Smith, Hua-Ling Tsai, et al.
Pageof 8